Targeted Lymphoma Cell Death by Novel Signal Transduction Modifications
Abstract
The proposed research set to; 1) create and characterize CD22-binding peptides that initiate signal transduction and apoptosis in non-Hodgkin's lymphoma (NHL), 2) optimize CD22-mediated signal transduction and lymphomacidal properties of ligand blocking anti-CD22 monoclonal antibodies (mAbs) and peptides with CD22-specific phosphatase inhibition and 3) correlate mAb-mediated and anti-CD22 peptide-mediated in vivo physiologic changes, efficacy, and tumor targeting using advanced immuno-positron emission topography (i-PET) and FDG-PET imaging technology. Since funding we have identified five peptides are based on CDR's of anti-CD22 mAbs. Peptide 5 has been characterized and described in the annual report for year 1 and 2. Within year 2 & 3 we have identified several other peptides that are more effective that peptide 5 and we have begun to characterize their specificity, signaling, cytotoxic and apoptotic potential. In addition we have initiated studies to identify CD22 binding peptides with greater affinity and specificity.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 14, 2010
- Accession Number
- ADA538568
Entities
People
- Joseph M. Tuscano
Organizations
- University of California